Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

11.1%

2 terminated out of 18 trials

Success Rate

88.9%

+2.4% vs benchmark

Late-Stage Pipeline

39%

7 trials in Phase 3/4

Results Transparency

19%

3 of 16 completed with results

Key Signals

3 with results89% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (1)
P 1 (3)
P 2 (1)
P 3 (2)
P 4 (5)

Trial Status

Completed16
Terminated2

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT05208268CompletedPrimary

A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer

NCT02032030Completed

Systematic Assessment and Targeted Improvement of Services Following Yearlong Surgical Outcomes Surveys

NCT03060746Completed

Helicobacter Pylori Sample Collection Protocol Pre Therapy Subjects

NCT00233389Phase 4CompletedPrimary

Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer

NCT03060733Completed

Helicobacter Pylori Sample Collection Protocol Post Therapy Subjects

NCT00125736Phase 4CompletedPrimary

A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium

NCT01376414Completed

H. Pylori Testing for Patients With Non-specific Upper Abdominal Pain in the Emergency Department

NCT02710994Phase 1CompletedPrimary

Pharmacodynamics and Safety of CDFR0209

NCT01167101Not ApplicableCompletedPrimary

Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection?

NCT00543868Phase 2CompletedPrimary

MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001)

NCT00272467Phase 4CompletedPrimary

Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy

NCT02299687Phase 1CompletedPrimary

Influence of CYP2C19 Polymorphism on PK/PD of Omeprazole

NCT00839488Phase 4TerminatedPrimary

Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis

NCT00239551Phase 4CompletedPrimary

Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer

NCT00762359Phase 3TerminatedPrimary

A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers

NCT00787254Phase 3CompletedPrimary

Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs

NCT00190255Completed

Pharmacogenetics of Gastrointestinal Bleeding

NCT00284908Phase 1Completed

Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers

Showing all 18 trials

Research Network

Activity Timeline